Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NYSE:BVSOTCMKTS:EDTXFNASDAQ:EMBCNASDAQ:IRMD On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBVSBioventus$6.77+1.7%$6.79$5.47▼$14.38$556.12M0.86437,755 shs2.03 million shsEDTXFSpectral Diagnostics$0.61+2.2%$0.60$0.32▼$0.65$174.25M0.236,370 shs334 shsEMBCEmbecta$9.64+3.9%$11.04$9.20▼$21.48$563.39M1.13491,521 shs1.09 million shsIRMDiRadimed$60.84+0.2%$55.57$42.34▼$63.29$773.58M0.9243,590 shs188,754 shsThe Next 7 Blockbuster Stocks for Growth InvestorsWondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBVSBioventus0.00%+3.36%+3.20%-25.03%+20.89%EDTXFSpectral Diagnostics0.00%-0.03%-1.01%+17.37%+74.37%EMBCEmbecta0.00%-1.33%-7.75%-21.50%-21.43%IRMDiRadimed0.00%+4.46%+4.64%+16.08%+41.32%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationBVSBioventus3.3461 of 5 stars3.30.00.00.02.34.21.3EDTXFSpectral Diagnostics0.4711 of 5 stars0.05.00.00.01.50.00.0EMBCEmbecta4.4137 of 5 stars3.21.03.30.01.93.33.8IRMDiRadimed4.6971 of 5 stars2.52.02.54.43.23.31.9Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceBVSBioventus 2.67Moderate Buy$14.33111.72% UpsideEDTXFSpectral Diagnostics 0.00N/AN/AN/AEMBCEmbecta 2.33Hold$19.33100.55% UpsideIRMDiRadimed 3.00Buy$72.0018.34% UpsideCurrent Analyst Ratings BreakdownLatest EDTXF, EMBC, IRMD, and BVS Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/23/2025EMBCEmbectaBTIG ResearchSubscribe to MarketBeat All Access for the recommendation accuracy ratingSet Price TargetBuy ➝ Buy$25.005/23/2025EMBCEmbectaMizuhoSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetNeutral ➝ Neutral$15.00 ➝ $13.005/7/2025BVSBioventusCraig HallumSubscribe to MarketBeat All Access for the recommendation accuracy ratingSet Price TargetBuy ➝ Buy$15.004/10/2025EMBCEmbectaMizuhoSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageNeutral$15.004/9/2025EMBCEmbectaMizuhoSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeHold(Data available from 6/29/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookBVSBioventus$567.70M0.98$0.54 per share12.58$2.80 per share2.42EDTXFSpectral Diagnostics$1.67M104.34N/AN/A($0.07) per share-8.72EMBCEmbecta$1.12B0.50$3.34 per share2.89($12.80) per share-0.75IRMDiRadimed$73.24M10.57$1.58 per share38.45$6.85 per share8.88Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateBVSBioventus-$156.23M-$0.48N/A14.72N/A-7.11%15.61%4.01%N/AEDTXFSpectral Diagnostics-$11.24M-$0.07N/A∞N/A-1,078.10%N/A-336.97%8/7/2025 (Estimated)EMBCEmbecta$78.30M$0.9010.713.140.614.89%-19.67%12.27%8/8/2025 (Estimated)IRMDiRadimed$19.23M$1.5539.2530.42N/A26.33%23.28%20.59%7/30/2025 (Estimated)Latest EDTXF, EMBC, IRMD, and BVS EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/9/2025Q1 2025EDTXFSpectral DiagnosticsN/A-$0.03N/A-$0.03N/A$0.40 million5/9/2025Q2 2025EMBCEmbecta$0.66$0.70+$0.04$0.40$261.77 million$259.00 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthBVSBioventusN/AN/AN/AN/AN/AEDTXFSpectral DiagnosticsN/AN/AN/AN/AN/AEMBCEmbecta$0.606.22%N/A66.67%N/AIRMDiRadimed$0.681.12%N/A43.87%1 YearsLatest EDTXF, EMBC, IRMD, and BVS DividendsAnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date5/5/2025EMBCEmbectaquarterly$0.154.51%5/28/20255/28/20256/13/20255/5/2025IRMDiRadimedquarterly$0.171.3%5/20/20255/20/20255/30/2025(Data available from 1/1/2013 forward)Compare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioBVSBioventus1.851.410.99EDTXFSpectral DiagnosticsN/A0.090.08EMBCEmbectaN/A2.481.83IRMDiRadimedN/A8.877.62Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipBVSBioventus62.94%EDTXFSpectral DiagnosticsN/AEMBCEmbecta93.83%IRMDiRadimed92.34%Insider OwnershipCompanyInsider OwnershipBVSBioventus33.00%EDTXFSpectral Diagnostics1.50%EMBCEmbecta0.42%IRMDiRadimed36.80%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableBVSBioventus1,20082.14 million54.46 millionNot OptionableEDTXFSpectral Diagnostics29285.52 million281.24 millionNot OptionableEMBCEmbecta2,10058.44 million58.20 millionOptionableIRMDiRadimed11012.72 million8.04 millionOptionableEDTXF, EMBC, IRMD, and BVS HeadlinesRecent News About These CompaniesCopeland Capital Management LLC Purchases 14,981 Shares of iRadimed Corporation (NASDAQ:IRMD)June 28 at 6:02 AM | marketbeat.comiRadimed Corporation (NASDAQ:IRMD) Shares Sold by Rhumbline AdvisersJune 22, 2025 | marketbeat.comProsperity Wealth Management Inc. Acquires Shares of 6,595 iRadimed Corporation (NASDAQ:IRMD)June 18, 2025 | marketbeat.comNew Strong Sell Stocks for June 12thJune 12, 2025 | zacks.comUBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Purchases 8,774 Shares of Iradimed Corporation (NASDAQ:IRMD)June 11, 2025 | marketbeat.comTwo Sigma Investments LP Sells 21,924 Shares of Iradimed Corporation (NASDAQ:IRMD)June 6, 2025 | marketbeat.comAre Investors Undervaluing IRADIMED CORPORATION (NASDAQ:IRMD) By 34%?June 2, 2025 | finance.yahoo.comSquarepoint Ops LLC Has $867,000 Stock Holdings in Iradimed Corporation (NASDAQ:IRMD)June 2, 2025 | marketbeat.comMillennium Management LLC Cuts Stock Position in Iradimed Corporation (NASDAQ:IRMD)June 2, 2025 | marketbeat.comKings Path Partners LLC Has $649,000 Holdings in Iradimed Corporation (NASDAQ:IRMD)May 31, 2025 | marketbeat.comIradimed (NASDAQ:IRMD) Stock Price Up 8% - Here's What HappenedMay 30, 2025 | marketbeat.comTwo Sigma Advisers LP Has $2.04 Million Holdings in Iradimed Corporation (NASDAQ:IRMD)May 30, 2025 | marketbeat.comIradimed Corporation Announces FDA Clearance for Next-Generation MRidium® 3870 IV Infusion Pump SystemMay 29, 2025 | quiverquant.comQIRADIMED CORPORATION Announces FDA 510(k) Clearance for MRidium® 3870 Infusion Pump SystemMay 29, 2025 | globenewswire.comIradimed Corporation (NASDAQ:IRMD) Shares Sold by Man Group plcMay 29, 2025 | marketbeat.comIRADIMED CORPORATION (NASDAQ:IRMD) Released Earnings Last Week And Analysts Lifted Their Price Target To US$71.00May 9, 2025 | finance.yahoo.comIradimed Corp Bottom Line Rises In Q1May 6, 2025 | nasdaq.comIRadimed Corporation (NASDAQ:IRMD) Q1 2025 Earnings Call TranscriptMay 6, 2025 | msn.comIradimed Announces Quarterly ResultsMay 5, 2025 | baystreet.caIradimed stock surges as Q1 earnings top estimatesMay 5, 2025 | investing.comIRADIMED CORPORATION (IRMD) Q1 2025 Earnings Call TranscriptMay 5, 2025 | seekingalpha.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeEDTXF, EMBC, IRMD, and BVS Company DescriptionsBioventus NYSE:BVS$6.77 +0.11 (+1.65%) Closing price 06/27/2025 04:00 PM EasternExtended Trading$6.76 -0.01 (-0.15%) As of 06/27/2025 05:54 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Bioventus Inc., a medical device company, focuses on developing and commercializing treatments that engage and enhance the body's natural healing process in the United States and internationally. The company's product portfolio includes pain treatments, which comprise non-surgical pain injection therapies, as well as peripheral nerve stimulation products, such as Durolane, GELSYN-3, and SUPARTZ for the treatment of knee osteoarthritis and Stimrouter to treat chronic peripheral pain. Its surgical solutions comprise bone graft substitutes that increase bone formation to stimulate bone healing in spinal fusions and other orthopedic surgeries; and ultrasonic products used for precise bone cutting and sculpting, soft tissue management, and tissue debridement, in various surgeries, including minimally invasive applications. The company's product include, Osteoamp, an allograft-derived bone graft for bone grafting procedures; Exponent matrix for posterolateral spine procedures; Purebone for bone grafting procedures; Signafuse bone graft; Interfuse bone graft; Osteomatrix+ synthetic bone graft; Extractor for autologous cell and bone marrow extraction; reficio bone matrix; nexus ultrasonic surgical system; bonescalpel surgical solution; SonaStar for surgical procedures; and SonicOne ultrasonic cleansing and debridement system. The company's restorative therapies include a bone stimulation system and devices to help patients regain leg or hand function due to stroke, multiple sclerosis, or other central nervous system disorders. Its products include exogen, a bone healing system; L300 GO, a foot drop system; H200 rehabilitation system; Vector, a body weight support system; and Bioness integrated therapy system. It developing Talisman pulse generator and receiver for peripheral nerve stimulation. The company was founded in 2011 and is headquartered in Durham, North Carolina.Spectral Diagnostics OTCMKTS:EDTXF$0.61 +0.01 (+2.24%) As of 06/27/2025 12:14 PM EasternSpectral Medical Inc. focuses on the development and commercialization of products for the treatment of septic shock in the United States, Italy, Ireland, and internationally. The company markets Endotoxin Activity Assay, a rapid in vitro diagnostic test for the detection of components of gram negative bacterial cell wall; and Polymyxin B Hemoperfusion, a therapeutic hemoperfusion device that removes endotoxin from the bloodstream. It also develops and manufactures monoclonal and polyclonal antibodies, recombinant cardiac proteins, and calibrators for use in the research and development, as well as products that are manufactured by other diagnostic companies. The company was formerly known as Spectral Diagnostics Inc. and changed its name to Spectral Medical Inc. in December 2014. Spectral Medical Inc. was incorporated in 1991 and is headquartered in Toronto, Canada.Embecta NASDAQ:EMBC$9.64 +0.36 (+3.88%) Closing price 06/27/2025 04:00 PM EasternExtended Trading$9.64 0.00 (-0.01%) As of 06/27/2025 04:35 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Embecta Corp., a medical device company, focuses on the provision of various solutions to enhance the health and wellbeing of people living with diabetes. Its products include pen needles, syringes, and safety injection devices, as well as digital applications to assist people with managing patient's diabetes. The company primarily sells its products to wholesalers and distributors in the United States and internationally. Embecta Corp. was founded in 1924 and is headquartered in Parsippany, New Jersey.iRadimed NASDAQ:IRMD$60.84 +0.13 (+0.21%) Closing price 06/27/2025 04:00 PM EasternExtended Trading$60.82 -0.02 (-0.02%) As of 06/27/2025 05:18 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.IRadimed Corp. engages in the development, manufacture, marketing, and distribution of Magnetic Resonance Imaging compatible medical devices. It also provides a non-magnetic Intravenous infusion pump system that is specifically designed for use during MRI procedures. The company was founded by Roger Susi in July 1992 and is headquartered in Winter Springs, FL. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Nike Stock: The Mother of All Comebacks Might Have Just Begun EA Just Caught a Monster Upgrade: Bullish Breakout Ahead? Addition by Subtraction: Intel’s New Strategy Energizes Investors Apple: The Mag 7’s Dead Money Stock or AI Cash Cow in the Making? NVIDIA’s Stock Price Hits New Highs: This Is What’s Next Micron: A Hot Buy Heats Up, Fresh All-Time Highs Are Coming Rocket Lab: Europe Comes Calling as Momentum Builds Broadcom’s Big VMware Update: A Threat to Public Cloud Giants? Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
